Universal Vision Biotechnology Co Ltd (TWO:3218) — Market Cap & Net Worth
Market Cap & Net Worth: Universal Vision Biotechnology Co Ltd (3218)
Universal Vision Biotechnology Co Ltd (TWO:3218) has a market capitalization of $355.02 Million (NT$11.27 Billion) as of September 16, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #14085 globally and #563 in its home market, demonstrating a -2.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Universal Vision Biotechnology Co Ltd's stock price NT$133.00 by its total outstanding shares 84724899 (84.72 Million). Also see balance sheet size of Universal Vision Biotechnology Co Ltd for a full breakdown of the balance sheet.
Universal Vision Biotechnology Co Ltd Market Cap History: 2015 to 2026
Universal Vision Biotechnology Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $44.54 Million to $355.02 Million (20.53% CAGR). Also see 3218 operating cash flow for how efficiently the company converts equity into cash flow.
Universal Vision Biotechnology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Universal Vision Biotechnology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 3218 live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.09x
Universal Vision Biotechnology Co Ltd's market cap is 0.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.37x
Universal Vision Biotechnology Co Ltd's market cap is 0.37 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $43.52 Million | $1.07 Billion | $91.80 Million | 0.04x | 0.47x |
| 2017 | $52.90 Million | $1.08 Billion | $120.09 Million | 0.05x | 0.44x |
| 2018 | $52.37 Million | $1.19 Billion | $161.48 Million | 0.04x | 0.32x |
| 2019 | $145.77 Million | $1.42 Billion | $238.00 Million | 0.10x | 0.61x |
| 2020 | $530.02 Million | $2.05 Billion | $483.21 Million | 0.26x | 1.10x |
| 2021 | $636.64 Million | $2.63 Billion | $595.43 Million | 0.24x | 1.07x |
| 2022 | $718.49 Million | $3.49 Billion | $850.53 Million | 0.21x | 0.84x |
| 2023 | $719.49 Million | $4.08 Billion | $1.05 Billion | 0.18x | 0.69x |
| 2024 | $533.86 Million | $4.23 Billion | $1.06 Billion | 0.13x | 0.50x |
| 2025 | $389.72 Million | $4.20 Billion | $1.04 Billion | 0.09x | 0.37x |
Competitor Companies of 3218 by Market Capitalization
Companies near Universal Vision Biotechnology Co Ltd in the global market cap rankings as of September 16, 2026. Review 3218 goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Universal Vision Biotechnology Co Ltd by market ranking:
- HCA Healthcare, Inc. (NYSE:HCA): Ranked #288 globally with a market cap of $91.34 Billion USD.
- Fresenius SE & Co. KGaA (XETRA:FRE): Ranked #911 globally with a market cap of $29.19 Billion USD ( €24.97 Billion EUR).
- FRESENIUS SE+CO. ADR 1/4 (F:FREA): Ranked #1001 globally with a market cap of $26.87 Billion USD ( €22.98 Billion EUR).
- Tenet Healthcare Corporation (NYSE:THC): Ranked #1234 globally with a market cap of $20.93 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #288 | HCA Healthcare, Inc. | NYSE:HCA | $91.34 Billion | $423.82 |
| #911 | Fresenius SE & Co. KGaA | XETRA:FRE | $29.19 Billion | €45.39 |
| #1001 | FRESENIUS SE+CO. ADR 1/4 | F:FREA | $26.87 Billion | €10.20 |
| #1234 | Tenet Healthcare Corporation | NYSE:THC | $20.93 Billion | $260.85 |
Universal Vision Biotechnology Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Universal Vision Biotechnology Co Ltd's market cap moved from $44.54 Million to $ 355.02 Million, with a yearly change of 20.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$355.02 Million | -8.90% |
| 2025 | NT$389.72 Million | -27.00% |
| 2024 | NT$533.86 Million | -25.80% |
| 2023 | NT$719.49 Million | +0.14% |
| 2022 | NT$718.49 Million | +12.86% |
| 2021 | NT$636.64 Million | +20.12% |
| 2020 | NT$530.02 Million | +263.61% |
| 2019 | NT$145.77 Million | +178.34% |
| 2018 | NT$52.37 Million | -1.01% |
| 2017 | NT$52.90 Million | +21.55% |
| 2016 | NT$43.52 Million | -2.28% |
| 2015 | NT$44.54 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Universal Vision Biotechnology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $355.02 Million USD |
| MoneyControl | $355.02 Million USD |
| MarketWatch | $355.02 Million USD |
| marketcap.company | $355.02 Million USD |
| Reuters | $355.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Universal Vision Biotechnology Co Ltd
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. The company offers optical instruments, eyeglasses, contact lenses, and eyeglass accessories. It is also involved in eyeglasses optometry and dispensing services and leasing of medical devices. In addition, the company offers hospital management, optometric, and technical consultancy analysis, as we… Read more